Log in

NASDAQ:IMMUImmunomedics Stock Price, Forecast & News

$40.00
-0.66 (-1.62 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$39.40
Now: $40.00
$41.02
50-Day Range
$34.23
MA: $40.70
$44.41
52-Week Range
$8.80
Now: $40.00
$44.91
Volume778,171 shs
Average Volume3.51 million shs
Market Capitalization$9.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.41
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Read More
Immunomedics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IMMU
CUSIP45290710
Phone973-605-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Price / Sales31,881.93
Book Value$1.38 per share

Profitability

Net Income$-357,190,000.00

Miscellaneous

Employees346
Market Cap$9.25 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$40.00
-0.66 (-1.62 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

How has Immunomedics' stock been impacted by Coronavirus?

Immunomedics' stock was trading at $13.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IMMU shares have increased by 199.0% and is now trading at $40.00.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Immunomedics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Immunomedics
.

When is Immunomedics' next earnings date?

Immunomedics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Immunomedics
.

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) issued its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.39.
View Immunomedics' earnings history
.

What price target have analysts set for IMMU?

13 brokerages have issued 1-year price objectives for Immunomedics' stock. Their forecasts range from $22.00 to $60.00. On average, they expect Immunomedics' share price to reach $42.54 in the next twelve months. This suggests a possible upside of 6.3% from the stock's current price.
View analysts' price targets for Immunomedics
.

Has Immunomedics been receiving favorable news coverage?

News articles about IMMU stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immunomedics earned a news impact score of -2.6 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Immunomedics
.

Who are some of Immunomedics' key competitors?

What other stocks do shareholders of Immunomedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Celgene (CELG), Micron Technology (MU), Seattle Genetics (SGEN), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), ImmunoGen (IMGN), Novavax (NVAX), Advanced Micro Devices (AMD) and Netflix (NFLX).

Who are Immunomedics' key executives?

Immunomedics' management team includes the following people:
  • Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)
  • Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)
  • Mr. Scott A. Canute MBA, Exec. Director (Age 58)
  • Mr. Brendan Delaney, Chief Commercial Officer (Age 44)
  • Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

Who are Immunomedics' major shareholders?

Immunomedics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.16%), FMR LLC (5.01%), Point72 Asset Management L.P. (1.89%), Marshall Wace North America L.P. (1.13%), Deerfield Management Company L.P. Series C (1.11%) and Avidity Partners Management LP (0.83%). Company insiders that own Immunomedics stock include Avoro Capital Advisors Llc and Bryan Ball.
View institutional ownership trends for Immunomedics
.

Which major investors are selling Immunomedics stock?

IMMU stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Victory Capital Management Inc., Frontier Capital Management Co. LLC, First Light Asset Management LLC, Peregrine Capital Management LLC, State of Wisconsin Investment Board, Nicholas Investment Partners LP, and Rhenman & Partners Asset Management AB.
View insider buying and selling activity for Immunomedics
.

Which major investors are buying Immunomedics stock?

IMMU stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Vanguard Group Inc., TimesSquare Capital Management LLC, Avidity Partners Management LP, Assenagon Asset Management S.A., Point72 Asset Management L.P., and Orbimed Advisors LLC. Company insiders that have bought Immunomedics stock in the last two years include Avoro Capital Advisors Llc, and Bryan Ball.
View insider buying and selling activity for Immunomedics
.

How do I buy shares of Immunomedics?

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $40.00.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $9.25 billion and generates $290,000.00 in revenue each year. The biopharmaceutical company earns $-357,190,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Immunomedics employs 346 workers across the globe.

What is Immunomedics' official website?

The official website for Immunomedics is www.immunomedics.com.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.